# EDGAR Filing Document

**Accession Number:** 0000874716
**File Stem:** 0001567619-23-003220
**Filing Date:** 2023-2
**Character Count:** 7762
**Document Hash:** 33b215d27983b73ca8842cae0fe80457
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001567619-23-003220.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0001567619-23-003220

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230214

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230216

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MCKEON BRIAN P
- **CENTRAL INDEX KEY:** 0001219445

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19271
- **FILM NUMBER:** 23639857

**MAIL ADDRESS:**
- **STREET 1:** IDEXX LABORATORIES
- **STREET 2:** ONE IDEXX DRIVE
- **CITY:** WESTBROOK
- **STATE:** ME
- **ZIP:** 04092
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IDEXX LABORATORIES INC /DE
- **CENTRAL INDEX KEY:** 0000874716
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 010393723
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ONE IDEXX DRIVE
- **CITY:** WESTBROOK
- **STATE:** ME
- **ZIP:** 04092-2041
- **BUSINESS PHONE:** 2075560300

**MAIL ADDRESS:**
- **STREET 1:** ONE IDEXX DRIVE
- **CITY:** WESTBROOK
- **STATE:** ME
- **ZIP:** 04092-2041

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IDEXX CORP / DE
- **DATE OF NAME CHANGE:** 19600201

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MCKEON BRIAN P<br><sub>(Last) (First) (Middle)</sub><br>ONE IDEXX DRIVE<br><sub>(Street)</sub><br>WESTBROOK, ME 04092<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-14 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Executive VP & CFO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>IDEXX LABORATORIES INC /DE [ IDXX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-14 |  | M |  | 504 | A | $0 | 28814.6426 | D |  |
| Common Stock | 2023-02-14 |  | M |  | 435 | A | $0 | 29249.6426 | D |  |
| Common Stock | 2023-02-14 |  | M |  | 433 | A | $0 | 29682.6426 | D |  |
| Common Stock | 2023-02-14 |  | M |  | 253 | A | $0 | 29935.6426 | D |  |
| Common Stock | 2023-02-14 |  | M |  | 303 | A | $0 | 30238.6426 | D |  |
| Common Stock | 2023-02-14 |  | F |  | 1208 | D | $503.65 | 29030.6426 | D |  |
| Common Stock |  |  |  |  |  |  |  | 18050 | I | by Estony McKeon Family LLC |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | 2023-02-14 |  | M |  |  | 504 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 504 | <sup>(6)</sup> | 5320 | D |  |
| Restricted Stock Unit | <sup>(2)</sup> | 2023-02-14 |  | M |  |  | 435 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 435 | <sup>(6)</sup> | 4885 | D |  |
| Restricted Stock Unit | <sup>(3)</sup> | 2023-02-14 |  | M |  |  | 433 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 433 | <sup>(6)</sup> | 4452 | D |  |
| Restricted Stock Unit | <sup>(4)</sup> | 2023-02-14 |  | M |  |  | 253 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 253 | <sup>(6)</sup> | 4199 | D |  |
| Restricted Stock Unit | <sup>(5)</sup> | 2023-02-14 |  | M |  |  | 303 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 303 | <sup>(6)</sup> | 3896 | D |  |

---

### Footnotes:

(1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning  February 14, 2019.

(2) Each RSU represents a contingent right to receive one share of Issuer common stock. This  RSU grant vests in five annual installments, beginning February 14, 2020.

(3) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021.

(4) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022.

(5) Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023.

(6) Not applicable.

**Signature:** /s/ Lily J. Lu, Attorney-in-Fact for Brian P. McKeon  
**Date:** 2023-02-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**